Psychophysiology in the Study of Psychological Trauma: Where Are We Now and Where Do We Need to Be?

D.T. Acheson, M.A. Geyer and V.B. Risbrough

Abstract Posttraumatic stress disorder (PTSD) is a major public health concern, which has been seeing increased recent attention partly due to the wars in Iraq and Afghanistan. Historically, research attempting to understand the etiology and treatment of PTSD has made frequent use of psychophysiological measures of arousal as they provide a number of advantages in providing objective, non-selfreport outcomes that are closely related to proposed neurobiological mechanisms and provide opportunity for cross-species translation. Further, the ongoing shift in classification of psychiatric illness based on symptom clusters to specific biological, physiological, and behavioral constructs, as outlined in the US National Institute of Mental Health (NIMH) Research Domain Criteria project (RDoC), promises that psychophysiological research will continue to play a prominent role in research on trauma-related illnesses. This review focuses on the current state of the knowledge regarding psychophysiological measures and PTSD with a focus on physiological markers associated with current PTSD symptoms, as well as markers of constructs thought to be relevant to PTSD symptomatology (safety signal learning, fear extinction), and psychophysiological markers of risk for developing PTSD following trauma. Future directions and issues for the psychophysiological study of trauma including traumatic brain injury (TBI), treatment outcome studies, and new wearable physiological monitoring technologies are also discussed.

Keywords Psychophysiology \cdot PTSD \cdot Startle \cdot Heart rate variability \cdot Electrodermal response \cdot TBI

D.T. Acheson · M.A. Geyer · V.B. Risbrough (\boxtimes)

Department of Psychiatry, University of California San Diego,

9500 Gilman Dr. Mail Code 0804, La Jolla, CA 92093-0804, USA e-mail: vrisbrough@ucsd.edu

V.B. Risbrough Center for Excellence in Stress and Mental Health, VA San Diego Healthcare System, San Diego, USA

M.A. Geyer Mental Illness Research, Education and Clinical Center, VA San Diego Healthcare System, San Diego, USA

Curr Topics Behav Neurosci (2014) 21: 157–183 157 DOI: 10.1007/7854_2014_346 © Springer-Verlag Berlin Heidelberg 2014 Published Online: 27 August 2014

Contents

1 Introduction

Posttraumatic stress disorder (PTSD) is a major public health concern with lifetime prevalence rates in the USA estimated to be 6.8–12.2 %, and 12-month prevalence rates estimated to be 3.5 % (Breslau [2009\)](#page-20-0). Due to the wars in Iraq and Afghanistan, PTSD has received significant attention in the past 10–13 years, in terms of both popular media coverage and funds directed toward its research. This attention is warranted, given that rates of PTSD have increased in service members by 656 % since 2001 and the cost to the US Department of Defense (DoD) for treating these service members doubled between 2007 and 2012 (Blakeley and Jansen [2013](#page-20-0) Congressional Research Service Report). In addition, it is important to note that PTSD affects more than just combat veterans and occurs in civilians following physical and sexual assaults, forced captivity, muggings/robberies, motor vehicle accidents, natural disaster, and life-threatening illness among other events (Breslau [2009\)](#page-20-0). The DSM-IV classification of PTSD consisted in exposure to the traumatic event, as well as 3 clusters of symptoms: re-experiencing, avoidance and numbing, and hyperarousal. With the recent publication of DSM-5, the definition has expanded into 4 symptom clusters: intrusion, avoidance, negative alterations in cognitions and mood, and alterations in arousal and reactivity. This expansion recognizes broader, more heterogeneous symptom expressions (such as dysphoria and anger) while allowing for more dynamic changes in arousal and reactivity. Current treatments for PTSD are mainly psychotherapy based (e.g., exposure therapy and cognitive therapy). Pharmacological treatments, such as serotonin-selective and serotonin-norepinephrine reuptake inhibitors (SSRI/SNRIs), have also achieved modest efficacy (Committee on treatment of posttraumatic stress disorder IoMotNA 2007).

There is a clear need for the development of novel preventive and therapeutic treatment strategies for PTSD via increased understanding of etiological and maintaining factors of the disorder (Baker et al. [2009\)](#page-19-0). To this end, there is a new focus on utilization of biological, physiological, and behavioral tools to enable a "paradigm shift" from sole reliance on self-report measures to assess symptom status and diagnosis for psychiatric disorders such as PTSD. The US National Institute of Mental Health (NIMH) Research Domain Criteria project (RDoC) represents a framework for research in this area, with an emphasis on developing a diagnostic classification scheme based upon valid observable markers of common biological processes across the range of currently identified diagnostic categories. The negative valence system (NVS) domain suggested by the NIMH contains the constructs of acute threat of "fear," potential harm or "anxiety," and sustained threat. The 2011 NVS working group meeting identified many of the physiological measures reviewed below as important research tools for understanding these constructs. Psychophysiological measures may have utility as static markers of these constructs, as well as dynamic markers of change enabling the elucidation of the roles of learning and memory processes in the expression of these constructs. Thus, psychophysiological measures are poised to play an important role in the future understanding of mental illness generally, and traumatic stress-related disorder characterized by negative valence states more specifically.

Psychophysiological outcome measures have a number of advantages in neuropsychiatric research. (1) Psychophysiological measures provide objective, nonself-report outcomes and thus are less subject to bias by the subject and/or researcher. (2) Physiological measures are quantifiable. (3) Compared to self-report symptom scales, physiological measures may represent more discrete symptom domains that probe specific neurobiological pathways enabling mechanistic study of neurobiological abnormalities underlying symptoms. (4) Physiological measures enable cross-species translation to examine causal mechanisms of psychophysiological abnormalities linked to trauma exposure that cannot be achieved with selfreport measures. The current manuscript will review the current state of knowledge on psychophysiological outcomes in PTSD with attention to their use as markers of current symptoms as well as markers of PTSD-related processes. We will also discuss these variables in terms of their sensitivity and selectivity for PTSD symptoms versus other anxiety and mood disorders and comorbid disorders such as traumatic brain injury (TBI). Further, we will discuss potential future avenues for integrating psychophysiology into emerging areas of PTSD research. We have limited our review to relatively common psychophysiological measures of arousal/ threat, including cardiovascular, electromyographic, and electrodermal measures.

2 Psychophysiological Markers of Current PTSD Symptoms

2.1 Cardiovascular Activity

Baseline: Current conceptualizations of PTSD, reflected in the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM 5; APA 2014) criteria, recognize that PTSD has a complex phenomenology expressed not just as

fear-based hyperarousal, but also as anhedonic and dysphoric emotional states. In contrast, earlier conceptualizations of the disorder, reflected in DSM-III through IV criteria, placed a larger emphasis on fear-related arousal. Given the past emphasis on arousal-related symptoms, research has long focused on identifying and understanding the psychophysiological basis of elevated arousal. Though studies have assessed the construct of arousal across a number of psychophysiological measures, an extensive body of work has focused on the cardiovascular system. Cardiovascular physiology is a convenient domain to focus on since it can be measured relatively easily using a number of different methods and equipment typically present in an emergency department or urgent care clinic. Further, some elements of cardiac physiology can be interpreted as a readout of sympathetic/ parasympathetic balance, which has long been theorized to be disrupted in PTSD (see below).

Blanchard et al. [\(1982](#page-20-0)) observed that Vietnam veterans with PTSD had higher resting baseline heart rate (HR) and blood pressure (BP) than Vietnam veterans without PTSD. These initial observations were later largely confirmed in a metaanalysis by Buckley and Kaloupek ([2001\)](#page-20-0), which reviewed 34 studies of resting cardiovascular activity in PTSD conducted up to that time. This meta-analysis found support for elevated resting HR and diastolic blood pressure (BP), though systolic BP levels were similar across PTSD subjects and healthy controls. A more recent meta-analysis of psychophysiological studies in PTSD (Pole [2007](#page-24-0)) reviewed 55 studies conducted until that time and also supported increased resting HR in PTSD relative to healthy controls. However, elevations in systolic and diastolic BP were only present under relaxed criteria for statistical significance.

While the evidence for altered cardiovascular activity at rest in PTSD appears fairly strong, some researchers have suggested a more nuanced relationship. First, some studies (i.e., Shalev et al. [1992](#page-25-0)) have failed to find HR differences in newonset PTSD. Further, Buckley and Kaloupek [\(2001](#page-20-0)) showed a greater effect size for HR in patients with chronic PTSD (>13 years). Taken together, these findings suggest that elevated HR may be a consequence of physiological changes driven by long-term PTSD. Second, studies monitoring cardiovascular activity over 24-h periods have suggested that HR and BP may fluctuate widely across the day, complicating previous studies (Muraoka et al. [1998;](#page-24-0) Buckley et al. [2004\)](#page-20-0). One study using 24-h HR monitoring did, however, confirm increased HR in veterans with PTSD, with more pronounced effects during the night, perhaps related to the sleep disturbances commonly associated with PTSD (Agorastos et al. [2013\)](#page-19-0). Third, there is disagreement among researchers regarding whether resting state activity is actually being measured in these studies, or if what is actually being captured are cardiovascular responses to a stressful situation/challenge induced by the testing environment (see below; Zoladz and Diamond [2013](#page-26-0)). Other studies suggest that PTSD subjects are hyperresponsive to stress or threat across a number of physiological markers, including HR, startle, and skin conductance (see below). Further, increased HR is not specific to PTSD, but is also reported in panic disorder and depression (Cohen et al. [2000](#page-20-0); Blechert et al. [2007](#page-20-0); Kamphuis et al. [2007\)](#page-22-0).

An additional marker of resting-state cardiovascular activity that is altered in PTSD is heart rate variability (HRV). HRV is a measure of the variation in time between heart beats, which indicates autonomic flexibility (the higher the variation, the more flexibility). HRV is most accurately measured via electrocardiogram; however, photoplethysmography is also utilized. HRV is measured as time-domain variables (e.g., changes in the standard deviation of beat–beat interval) and frequency domains using power spectral density analysis methods. Frequency components are thought to represent sympathetic and parasympathetic control over HR, with the high frequency domain (HF; $0.15-0.4$ Hz) representing parasympathetic or vagal tone, while the low frequency (LF; 0.04–0.15 Hz) is comprised of both parasympathetic and some sympathetic elements (see Heathers [2014](#page-22-0); Berntson et al. [1997](#page-20-0) for review). Finally, respiratory sinus arrhythmia, HRV due to respiration, is another measure of vagal control of autonomic activity. Reduced HRV is associated with mortality and cardiovascular symptoms in patients with PTSD, highlighting the clinical importance of these measures (Kubzansky et al. [2007\)](#page-23-0). There is growing evidence that both LF and HF are reduced in PTSD patients, which may be suggestive of an imbalance between sympathetic and parasympathetic drive on cardiovascular output (Cohen et al. [2000;](#page-20-0) Blechert et al. [2007;](#page-20-0) Jovanovic et al. [2009](#page-22-0)), though exceptions have been reported (Sahar et al. [2001](#page-25-0)). In a recent twin study of combat-related PTSD in Vietnam era veterans, Shah et al. [\(2013](#page-25-0)) found that HRV abnormalities (lower LF and HF) were present only in the twin with PTSD, suggesting that reduced HRV is an acquired consequence of the disorder. They also suggested that HRV abnormalities were not present in subjects with remitted PTSD, suggesting HRV reductions are indicative of symptom state. We have recently shown that HRV reductions (reduced HF) are also associated with new-onset PTSD symptoms in active duty marines who served in Iraq/Afghanistan, suggesting that reduced HRV is not related to age or chronicity of PTSD (Minassian et al. [2014](#page-23-0)). These studies have also shown that reductions in HRV in these populations are not due to depression or TBI, nor are they related to degree of combat exposure or deployment history per se (Shah et al. [2013](#page-25-0); Minassian et al. [2014\)](#page-23-0). Finally, reduced HRV is reported in untreated subjects (Minassian et al. [2014;](#page-23-0) Chang et al. [2013\)](#page-20-0), indicating that this phenotype is not due simply to medication side effects. Although HRV measures appear to be sensitive to PTSD symptoms, they are not specific to PTSD. Indeed, reduced HRV, in particular HF, may be a more general marker of anxiety disorders (Pittig et al. [2013](#page-24-0)) or even mental illness, as it is reduced across multiple disorders including anxiety, depression, bipolar disorder, and schizophrenia (Moon et al. [2013](#page-24-0)). It is possible that multiple mechanisms underlie the reductions in HRV across these diverse patient groups, or that

Response to Challenge: In contrast to resting-state cardiovascular markers, several studies have assessed cardiovascular activity in response to challenges from either loud acoustic stimuli (startle) or trauma-related cues. A large body of literature documents larger HR reactivity to startling sounds in PTSD patients (Pallmeyer et al. [1986;](#page-24-0) Shalev et al. [1992;](#page-25-0) Orr et al. [2002](#page-24-0)). Pole ([2007\)](#page-24-0) investigated 10 studies

reductions in HRV are due to the higher stress or allostatic load experienced by

those with neuropsychiatric illness (McEwen [2000\)](#page-23-0).

measuring HR response to loud acoustic stimuli and found that elevated HR response was among the most robust effects found using this paradigm. Pitman et al. [\(2006](#page-24-0)) examined elevated HR reactivity to sudden loud tone presentation in a twin sample of Vietnam veterans. They found elevated HR reactivity only in the twin with PTSD, indicating HR response is an acquired consequence of the disorder rather than a predisposing trait.

HR response to trauma-related reminder cues has also been examined, which may probe biological mechanisms relevant to fear memory processes. These studies typically involve either "standardized" cues, such as combat sounds (Liberzon et al. [1999\)](#page-23-0) that are held constant across the sample being studied, or "ideographic" cues which are tailored to be specific to each subject's traumatic experience. Pole [\(2007](#page-24-0)) reviewed 16 studies investigating HR response to standardized trauma cues and another 22 investigating HR response to ideographic trauma-related cues. Elevated HR response to standardized cues in PTSD emerged as one of the more robust effects in these paradigms. Support for increased HR responses to ideographic trauma cues was also found, though less robust than that for standardized cues. Recent studies have also supported these findings in both standardized (Adenauer et al. [2010](#page-19-0); Suendermann et al. [2010](#page-26-0); Ehlers et al. [2010](#page-21-0)) and ideographic trauma cues (Barkay et al. [2012](#page-20-0)). Barkay et al. [\(2012](#page-20-0)) have investigated the neurobiological correlates of this effect using PET imaging and found correlations between HR and rCBF in the orbitofrontal, precentral, and occipital regions of the cortex only in patients with PTSD and not in trauma-exposed non-PTSD subjects. These findings are suggestive that increased HR responses to trauma reminders may overlap in neural substrates (orbitofrontal cortex) with the reduced ability to inhibit fear responses (Shin et al. [2006\)](#page-25-0). In PTSD, there are correlations between HR response to trauma and norepinephrine concentrations in cerebrospinal fluid (Geracioti et al. [2008\)](#page-21-0), suggesting that central noradrenergic hypersignaling could play a role in this phenotype. It is unclear whether increased HR or other cardiovascular abnormalities are ameliorated by treatment, however, despite the use of noradrenergic reuptake inhibitors (Hoge et al. [2012\)](#page-22-0) as well as clinical trials of the alpha 1 receptor antagonist prazosin (Raskind et al. [2013\)](#page-25-0). Whether increases in HR are an epiphenomenon of increased centrally mediated fear responses, or are a core feature of PTSD pathology is unclear. One intriguing recent finding suggests that inhibitors of angiotensin I signaling, commonly given for hypertension, are associated with fewer PTSD symptoms in a cross-sectional sample of highly traumatized civilian populations (Khoury et al. [2012\)](#page-23-0). Other common hypertension medications were not associated with fewer symptoms, suggesting that the angiotensin pathway may play a role in PTSD-related pathology. Thus, more research is clearly needed to further elucidate pathways involved in elevated cardiovascular responses in PTSD.

Summary of Cardiovascular Markers of PTSD Symptom State: Cardiovascular physiology is an active and important area of research in PTSD, especially given reported links between PTSD and increased incidence of cardiovascular disease (Wentworth et al. [2013](#page-26-0)). While there is strong evidence that resting-state cardiovascular activity, as well as HR response to standardized and ideographic trauma cues, is altered in PTSD, this is still an active area of research that is not without

controversy. Specifically, the degree to which the testing situation contributes to findings of elevated HR in PTSD is unclear. The extent to which elevated HR is a feature of core PTSD pathology versus simply a consequence of chronic stress is also unknown. Some studies have suggested that HR soon after trauma may predict development of PTSD, suggestive of HR being a proxy for biological risk factors for PTSD (see below). However, a recent study suggests that HR is not altered in relatively "recent" PTSD cases after combat (Minassian et al. [2014](#page-23-0)), arguing against elevated HR as a risk factor. HR increases are also not specific to PTSD, but are increased in other anxiety disorders more generally. Research investigating the time course and neurobiological correlates of altered cardiovascular activity in PTSD is needed to further clarify these issues.

Many questions still remain for the association of HRV with PTSD symptoms. Although twin studies suggest that altered HRV is specific to PTSD symptom state, prospective studies are needed to confirm HRV measures as symptom dependent or markers of risk for PTSD (Baker et al. [2012](#page-19-0)). Similarly, although there is some evidence from cross-sectional analysis in small samples for symptom remission to be associated with normalization of HRV (Shah et al. [2013](#page-25-0)), longitudinal treatment studies are required to best address this question. The biological mechanisms responsible for HRV reductions in PTSD are also unclear. However, dysregulated sympathetic output (e.g., via increased noradrenergic tone, Geracioti et al. [2001](#page-21-0), [2008;](#page-21-0) Pietrzak et al. [2013\)](#page-24-0) and abnormalities in stress and immune systems have been identified as candidate mediators (Risbrough and Stein [2006;](#page-25-0) Eraly et al. [2014\)](#page-21-0).

2.2 Exaggerated Startle Response

Baseline: The startle response is a sensitive, noninvasive measure of central nervous system activity that is typically accessed via electromyographic (EMG) measurement of strength of contraction of the *orbicularis oculi* muscle controlling eyeblink in response to a sudden acoustic or tactile stimulus (Blumenthal et al. [2005\)](#page-20-0). Exaggerated startle is a symptom of PTSD according to the DSM 5 (APA 2014). Thus, it follows that larger baseline startle responding should be detectable in PTSD. However, evidence for increased startle reactivity under "baseline" conditions in PTSD is mixed, with some studies finding evidence for increased startle in PTSD relative to healthy controls and others finding equivalent startle responses (see Zoladz and Diamond [2013](#page-26-0) for a recent review of this literature). There are also some suggestions that increases in baseline startle may only occur in chronic PTSD patients or following certain forms of trauma, such as combat (Grillon and Baas [2003\)](#page-22-0). A significant problem with assessments of "baseline" startle is that it is very difficult to accurately assess this phenomenon. Startle reactivity is extremely plastic, and it is sensitive to many rapid and dynamic modes of inhibition such as habituation and sensorimotor gating, to emotional valence or experimental context, and of course is extremely sensitive to stimulus parameters such as intensity and duration of the startling stimulus, all of which will influence the detection of putative differences.

For example, startle is higher in PTSD patients under low-intensity startle stimuli but not high intensity (Butler et al. [1990](#page-20-0)), which may reflect a lowering of startle thresholds rather than an exaggeration of startle responses elicited by supra-threshold stimuli. Thus, more robust and reliable startle phenotypes in PTSD and other disorders are measured when comparing startle across multiple stimulus conditions and emotional contexts. Startle has also generally only been explored in terms of magnitude of the response (muscle contraction) compared to controls. However, selfreports of "increased startle" from patients may not simply reflect magnitude, but the probability of a response under subthreshold conditions, which has yet to be explored.

In Response to Challenge: Given the inconsistency of baseline startle changes in PTSD, it has been suggested that startle reactivity is higher in PTSD patients only when under threat; thus, this phenomenon is indicative of mechanisms related to increased stress responding rather than disruption of baseline arousal (Grillon and Baas [2003](#page-22-0)). Grillon et al. [\(1998](#page-22-0)) reported normal baseline but increased startle magnitude in Vietnam combat veterans with PTSD during anticipation of experimental electrical shock relative to non-PTSD veterans, demonstrating a higher response in situations of threat or stress in PTSD. Startle is also elevated in response to trauma reminders (imagery, trauma scripts) in PTSD patients (e.g., Cuthbert et al. [2003;](#page-20-0) McTeague et al. [2010](#page-23-0)); however, these tasks are relatively unique to individual laboratories and more difficult to generalize across studies. As a whole, these studies suggest that exaggerated startle in PTSD is not indicative of increased arousal at baseline, but is a physiological marker of heightened response to threat and heightened fear responses in the presence of trauma cues. Thus, startle is increasingly used as a quantitative measure of fear responding that complements self-report data on anxiety and stress to identify biological mechanisms underlying PTSD symptoms.

Studies have recently suggested that elevated startle to challenge in PTSD may be subject to gender differences. Kamkwalala et al. ([2012\)](#page-22-0) showed that women with PTSD had higher startle in a dark environment relative to a light environment than men and women without PTSD. However, this elevated "dark-enhanced" startle was not present in male subjects with PTSD. Further, dark-enhanced startle has been shown to be associated with pituitary adenylate cyclase-activating polypeptide receptor (PAC1) genotypes in females, a gene that interacts with estrogen and has also been associated with PTSD in females (Ressler et al. [2011](#page-25-0)). These studies represent a new avenue of PTSD research that is just coming to fruition in utilizing physiological markers as intermediate phenotypes to identify biological pathways related to PSTD risk.

Startle Habituation: Habituation is a non-associative learning process whereby an organism displays a reduction in some innate orienting or defensive response following repeated presentation of a stimulus (Halberstadt and Geyer [2009](#page-22-0)). Shalev et al. [\(2000](#page-25-0)) examined habituation of the startle and electrodermal response to loud acoustic stimulus in a sample of traumatized Israeli civilians tested at 1 week and 1 and 4 months following the traumatic event. Those who developed PTSD began to show reduced habituation in both measures beginning 1 month post-trauma, suggesting that reduced habituation may be an acquired sign of PTSD. The reduced startle habituation finding is confounded, however, as the methodology used to detect startle was flawed, with sample rates that were much too slow (50 Hz) to visualize the very fast on and off rate of a startle response which is typically measured with 1,000 Hz sampling rates. The reduced electrodermal habituation, however, supported earlier findings by this group (Shalev et al. [1992](#page-25-0)). Other studies had failed to detect reduced startle habituation in PTSD but were compromised by their use of inappropriately slow sampling rates (Pitman et al. [1987,](#page-24-0) [1993](#page-24-0); Orr and Pitman [1993](#page-24-0)). A more recent study in Croatian combat veterans found that PTSD and control groups did not differ in startle habituation as assessed by quantitative analysis of EMG reduction across trial; however, there was a reduction in PTSD subjects compared to controls when using nonparametric comparisons of a number of subjects who met criteria for habituation (lowest responding at the last trial) (Jovanovic et al. [2009\)](#page-22-0). This study also did not replicate habituation of the electrodermal response, a physiological marker of sympathetic nervous system arousal based on electrical conductivity across the skin due to sweat (see below). Thus, taken together across studies, evidence for differences in startle habituation in PTSD subjects is weak. PTSD subjects may exhibit reduced habituation of fear-potentiated startle during fear association training (Ressler et al. [2011](#page-25-0)). However, it is unclear whether this effect reflects reduced habituation to startling sounds or increased reactivity to the aversive stimuli used during fear conditioning. Reductions in habituation have been detected in other neuropsychiatric disorders (schizophrenia, panic disorder); thus, it is possible that reductions in habituation of the response may represent a pathology in a subset of patients across disorders, as such a phenotype would have substantial consequences for multiple behavioral functions (Geyer and Braff [1982;](#page-21-0) Ludewig et al. [2002a](#page-23-0), [b,](#page-23-0) [2003](#page-23-0), [2005\)](#page-23-0). Habituation is another "intermediate phenotype" that is being used to identify potential gene pathways disrupted in these disorders (Greenwood et al. [2012,](#page-21-0) [2013\)](#page-21-0).

Prepulse Inhibition of the Startle Response: Prepulse inhibition (PPI), the unlearned suppression of the startle reflex to an intense acoustic stimulus when immediately preceded by a weaker acoustic prepulse, is an operational measure of sensorimotor gating (Geyer et al. [1990;](#page-21-0) Geyer and Braff [1987\)](#page-21-0). PPI has been shown to be a robust but non-specific biomarker of psychiatric diagnosis. PPI performance is reduced compared to healthy controls in a number of neuropsychiatric disorders including panic disorder, obsessive compulsive disorder, schizophrenia, bipolar disorder, Tourette's disorder, and Huntington's disorder (Braff et al. [2001;](#page-20-0) Swerdlow et al. [2006](#page-26-0); Castellanos et al. [1996;](#page-20-0) Perry et al. [2001](#page-24-0); Ahmari et al. [2012;](#page-19-0) Ludewig et al. [2002a,](#page-23-0) [b\)](#page-23-0). Many of these disorders are linked to cortico-limbic circuit abnormalities (Kohl et al. [2013\)](#page-23-0). Given the evidence for PTSD to have disruptions in this circuit (Shin et al. [2006](#page-25-0)), PPI in PTSD subjects has also been examined. However, PPI associations with PTSD are inconsistent, with some studies showing significantly reduced PPI in PTSD patients (Ornitz and Pynoos [1989;](#page-24-0) Grillon et al. [1996,](#page-21-0) [1998](#page-22-0)), while others detected no differences or only marginal differences (Butler et al. [1990;](#page-20-0) Morgan et al. [1997;](#page-24-0) Lipschitz et al. [2005;](#page-23-0) Holstein et al. [2010;](#page-22-0) Vrana et al. [2013](#page-26-0)). Thus, additional research is needed to clarify or refute the presence of PPI deficits in PTSD.

Summary of altered startle plasticity in PTSD: Exaggerated startle responding in PTSD patients is seen fairly consistently, most predominantly under conditions of challenge or threat. Pole ([2007\)](#page-24-0) conducted a meta-analysis of 20 studies measuring startle response via orbicularis oculi EMG both at baseline and after manipulation of contextual threat. This analysis supported a significant increase in startle responses in PTSD; however, this effect was not as robust as elevated cardiovascular responses. Furthermore, increased startle response to threat is also not specific to PTSD, but is also reported in other disorders that are characterized by high physiological arousal and fear (e.g., panic disorder) but not generalized anxiety disorder (Grillon et al. [2009](#page-22-0); Grillon [2008](#page-22-0)). These findings suggest that disorders characterized by exaggerated startle may share an overlapping biological pathway. It is not clear, however, whether these effects are due to increased fear responses per se (e.g., via increased amygdala and/or insula circuit activation), or reduced ability to inhibit or modulate these responses appropriately (e.g., reduced modulation of amygdala output by hippocampal and cortical circuits; see below; Acheson et al. [2012;](#page-19-0) Klumpers et al. [2007](#page-23-0)).

Habituation and PPI are both measures of fundamental aspects of information processing that are disrupted in a number of psychiatric disorders and are to some degree heritable (Greenwood et al. [2007](#page-21-0)). However, there is relatively weak evidence at present for disruptions in PTSD. It is possible that disruption in these processes may indicate one of potentially many biological risk traits for neuropsychiatric disorders. Hence, further understanding of the genetic and neurobiological mechanisms underlying these phenotypes and their relationship to PTSD risk is worth further investigation. Indeed, PTSD is thought to share polygenic risk with other disorders that exhibit information processing deficits, such as bipolar disorder and schizophrenia (Nievergelt et al. in review; Solovieff et al. [2014](#page-25-0)).

While exaggerated startle per se is not unique to PTSD, it nonetheless represents a powerful method for exploring mechanisms underlying the development of PTSD symptoms. In animals, exaggerated startle phenotypes have long been utilized to test causal hypotheses of potential mechanisms underlying development of anxiety and fear-related behaviors after severe stress, including corticotropin-releasing factor and noradrenergic abnormalities (e.g., Risbrough and Stein [2006;](#page-25-0) Davis et al. [2010;](#page-20-0) Grillon et al. [2009\)](#page-22-0). In humans, utilization of startle plasticity as an intermediate phenotype is just now beginning to be exploited (Greenwood et al. [2012\)](#page-21-0). Further, questions of exaggerated startle magnitude versus reduced startle threshold in PTSD remain to be answered (Butler et al. [1990](#page-20-0)). Finally, surprisingly few pharmacological studies have thus far utilized startle to examine potential biological mechanisms of increased physiological responses in PTSD. Using a pharmacological challenge with the alpha 2 antagonist yohimbine, Morgan et al. [\(1995](#page-24-0)) showed that startle reactivity in PTSD patients may be via increased sensitivity to noradrenergic signaling.

2.3 Other Physiological Measures

Electrodermal Level/Response: In addition to HR and startle, researchers have examined electrodermal levels in PTSD both at resting baseline and in response to challenge. Electrodermal response, or the increase in electrical conductivity across the skin due to sweat, is a physiological marker of sympathetic nervous system arousal. A meta-analysis by Pole ([2007\)](#page-24-0) looked across 31 studies that measured resting electrodermal levels in subjects with PTSD versus controls and found support for significantly higher levels associated with PTSD, although the effect size was small. Blechert et al. [\(2007](#page-20-0)) found that PTSD subjects had higher resting baseline electrodermal level relative to both healthy controls and subjects with panic disorder, suggesting some diagnostic specificity. Resting electrodermal level has historically been reported to be reduced in subjects with depression versus healthy controls (Argyle [1991\)](#page-19-0), further suggesting that this measure may hold some diagnostic specificity.

Electrodermal response to challenge by standardized and ideographic trauma cues has also been examined in relation to PTSD. Pole [\(2007](#page-24-0)) looked across 22 studies and found medium effect sizes for elevated electrodermal response to both standard and ideographic cues in PTSD versus controls. Interestingly, Blechert et al. [\(2007](#page-20-0)) found blunted electrodermal response in PTSD when subjects were under threat of electrical shock, suggesting that there may be a difference in effect between challenge by reminder cue versus challenge by contextual threat (experimental shock). Similarly, McTeague et al. [\(2010](#page-23-0)) found that PTSD subjects with multiple traumas and more severe, chronic PTSD showed blunted defensive responses to ideographic imagery. More recently, Glover et al. ([2011\)](#page-21-0) showed overall elevations in fear-potentiated startle in a classical conditioning paradigm in PTSD subjects relative to controls; however, no differences were found in electrodermal responses. It is possible that startle reactivity measures may offer a wider measurable range to detect increased reactivity than skin conductance measures because startle baseline can be controlled by the experimenter (i.e., via adjustments of the intensity of acoustic pulse). Thus, it is possible that startle may be more sensitive to detecting differences in responses even under relatively high arousal states (e.g., under threat). Skin conductance, however, offers other significant advantages over startle, since it does not require a relatively invasive stimulus (e.g., acoustic pulse) for measurement. The passive nature of this measurement has also supported its use as a complementary tool in imaging studies in which subject movement must be severely limited (i.e., startle response movement can disrupt image processing).

Facial EMG: Facial EMG has been used as a physiological measure of emotional response and typically involves measurement of activity in the frontalis, corrugator, and zygomaticus major muscles involved in emotional facial expressions such as smiling and frowning. Pole [\(2007](#page-24-0)) found support for increased frontalis and corrugator EMG activity while viewing ideographic trauma cues (12 and 5 studies, respectively). Pole [\(2007](#page-24-0)) found no support for altered facial EMG activity at resting baseline, or in response to standardized trauma cues (12 and 6 studies, respectively).

Because these measures are (1) more sensitive to artifact (e.g., non-specific facial and head movements, talking) and (2) are not easily controlled or evoked parametrically compared to reflexive responses such as changes in HR, skin conductance, and startle, they have not been utilized widely. They do not offer cross-species translation nor have well-defined circuits; thus, they may have less utility in understanding biological mechanisms of PTSD.

Summary of Other Physiological Measures Associated with PSTD: Elevated resting-state electrodermal level may be a psychophysiological measure that is relatively specific to PTSD. However, this measure is susceptible to the same methodological difficulties as resting HR or baseline startle response, namely that it is difficult to eliminate contextual factors that may influence stress and thus electrodermal activity. Electrodermal response to challenge presents a complicated picture with findings varying dependent upon both subject-specific and testing protocol variables. There is support for an association between increased facial EMG reactivity specifically in response to idiographic trauma cues; however, the utility of this measure for further biological research is limited.

3 Psychophysiological Markers of PTSD-Relevant Constructs: Fear and Sustained Anxiety

Safety Signal Learning: Safety signal learning is the process by which an individual learns to inhibit a learned fear response in the presence of a cue signaling absence of danger. This process is directly relevant to PTSD phenomenology insofar as PTSD is in part characterized by altered reactivity to trauma-related cues even in "safe" environments. Safety signal learning can be measured by assessing responses to a CS− that is never associated with an aversive event versus a CS+ that is contiguous with an aversive event, or via a specific CS that predicts absence of the aversive event when given in conjunction with the CS+. Using the latter paradigm, Jovanovic et al. [\(2010](#page-22-0)) recently tested this process in a sample of trauma-exposed civilians who were healthy, had PTSD, had major depression, or had comorbid PTSD and major depression with fear-potentiated startle as the primary outcome variable. Subjects learned that a cue predicted a blast of air to the throat, but that when this cue was presented along with another cue (the safety signal), the blast of air would not occur. Subjects with PTSD and comorbid PTSD/major depression failed to show inhibition of the potentiated startle response in the presence of the safety cue. Inability of subjects with PTSD to inhibit responding to a safety signal was also confirmed in the former paradigm, a simple CS+/CS− discrimination learning task (Jovanovic et al. [2013\)](#page-22-0). Andero et al. [\(2013](#page-19-0)) found associations between the ability to learn to discriminate between the CS+ (danger) and CS− (safety) are impaired in subjects with a single nucleotide polymorphism (SNP) on the opioid receptor 1-like gene which encodes for the amygdala nociception/orphanin FQ receptor involved in pain processing. This SNP was also associated with greater PTSD symptoms, providing

further evidence for impaired safety signal processing in PTSD as well as a putative biological pathway for this effect. These results, though preliminary and in need of replication, suggest that failure to learn to distinguish between environmental cues signaling danger versus safety may be an important process that is impaired in PTSD.

Fear Extinction: Fear extinction is the process by which an organism learns that a cue that once signaled threat no longer does so, thus resulting in a progressive reduction in defensive physiological responding in the presence of this cue. Extinction of psychophysiological fear responding has long been considered a putative model of PTSD process due to its similarity to naturalistic recovery from trauma experience. Orr et al. [\(2000](#page-24-0)) and Peri et al. ([2000\)](#page-24-0) showed that PTSD patients failed to extinguish a conditioned electrodermal response to a cue signaling electrical shock or loud acoustic stimuli, respectively. Subsequent studies using electrodermal responses as the dependent variable have largely supported these original findings (e.g., Wessa and Flor [2007;](#page-26-0) Blechert et al. [2007](#page-20-0)). Norrholm et al. [\(2011](#page-24-0)) examined fear extinction in PTSD using fear-potentiated startle to a cue signaling an aversive air puff to the throat and found that PTSD patients showed greater potentiated startle in the early and middle portions of extinction training. This finding suggests that enhanced initial fear conditioning produced a greater "fear load" that the PTSD patients had to extinguish. This increased fear responding is also associated with specific symptom clusters of PTSD, re-experiencing (Glover et al. [2011\)](#page-21-0), indicating this paradigm likely probes neural mechanisms of trauma memory.

Not all studies have found evidence for delay of fear extinction learning in PTSD. Milad et al. [\(2008](#page-23-0)) found equal levels of extinction performance, as measured by electrodermal response, in combat-related PTSD compared to combatexposed monozygotic twins without PTSD and controls. However, the PTSD twins failed to recall this fear extinction learning when tested 24 h later. These results suggest that PTSD is not associated with a fear extinction learning deficit, but rather a fear extinction memory deficit. Further, this deficit appears to be an acquired sign of PTSD rather than an inherited trait. This difference in within-session learning results across these studies may be due to the physiological measures of fear used, startle versus skin conductance. The higher magnitude of the startle response to the conditioned cue in PTSD patients is providing a behavioral window to detect reduced/delayed extinction within session, which is not detectable via skin conductance responses (Glover et al. [2011](#page-21-0)). Taken together, these data suggest overall that there is higher fear responding in PTSD patients, which subsequently takes longer to extinguish fully and is less likely to be fully extinguished upon retesting. Additional research will be needed to determine the time point at which extinction deficits may occur, the most effective method for capturing such deficits, and the specific role these deficits play in PTSD symptomatology.

Summary of Psychophysiological Markers of PTSD-relevant Constructs: Psychophysiological markers have emerged as critical measures of unbiased fear responding to understand fear and anxiety domains disrupted in PTSD. These markers provide quantifiable assessments of autonomic processes that may not be adequately probed by self-report. They have been critical behavioral measures that

complement studies of the neural circuits underlying PTSD pathology, such as cortico-hippocampal–amygdala circuit function (Quirk et al. [2006\)](#page-25-0), that can be translated across species for further study of causal factors for PTSD symptoms or PTSD risk. The intriguing preliminary evidence for safety signal learning to be disrupted specifically in PTSD versus depression patients may indicate this is a potential "biomarker" of PTSD, but needs further research and replication. Extinction has shown to be impaired in a number of neuropsychiatric disorders as well as PTSD, including obsessive–compulsive disorder and schizophrenia (Holt et al. [2009;](#page-22-0) Milad et al. [2013](#page-23-0)), suggesting that extinction learning may probe common pathological circuits across these disorders. Impairment in these processes is further supported by imaging research showing impaired function and structure of the ventromedial prefrontal/orbitofrontal cortex in PTSD subjects, which are structures known to be central to fear extinction learning and memory (Shin et al. [2006\)](#page-25-0). Recent research suggests involvement of these areas in safety signal learning as well (Jovanovic et al. [2013](#page-22-0)). Finally, more recently, these paradigms have been utilized in healthy controls or PTSD patients to serve as proof of concept tests for novel treatments for fear-related disorders such as PTSD, with recent or ongoing tests of cannabinoid agonists (Rabinak et al. [2013](#page-25-0)), oxytocin (Acheson et al. [2013](#page-19-0)), glucocorticoids (de Quervain et al. [2011](#page-21-0)), and dopamine agonists (Haaker et al. [2013\)](#page-22-0), among others. It remains to be determined how predictive these paradigms will be for treatment efficacy; however, this is an exciting avenue for PTSD drug discovery.

4 Psychophysiological Markers of Risk for Developing PTSD Following Trauma

Trait Markers: Given that elevated physiological reactivity is a common finding in those with current PTSD, researchers have explored the possibility that this elevated reactivity might serve as a marker of risk prior to or immediately following the traumatic experience. Several studies examined the relationship between HR shortly following trauma and later development of PTSD and found that elevated HR following trauma predicted development of PTSD symptoms (Bryant et al. [2000;](#page-20-0) Kassam-Adams et al. [2005](#page-23-0); Shalev et al. [1998](#page-25-0); Zatzick et al. [2005](#page-26-0); Kuhn et al. [2006;](#page-23-0) Gould et al. [2011\)](#page-21-0). Though numerous exceptions have been reported (Blanchard et al. [2002;](#page-20-0) Buckley et al. [2004;](#page-20-0) Ehring et al. [2008;](#page-21-0) Roitman et al. [2013;](#page-25-0) Price et al. [2014\)](#page-24-0). In a related study, Suendermann et al. [\(2010](#page-26-0)) found that HR response to trauma-related images in motor vehicle accident survivors 1 month after trauma predicted PTSD severity at 6 months after trauma. The inconsistency in these findings may be due to the fact that cardiovascular activity assessed immediately post-trauma in the ambulance or emergency department may be subject to too many contextual variables, methodological inconsistencies, or ceiling effects that may limit reproducibility of findings. Newer technology allowing for ambulatory monitoring in the days following trauma (see below) may prove more useful in determining at which time points and under what circumstances post-trauma HR may be most predictive of future PTSD.

While these studies of peri-traumatic HR suggest potential clinical utility as a marker of risk in traumatized individuals, they tell us little about who might be at risk for trauma before the event happens. Toward answering this question, Pitman et al. [\(2006](#page-24-0)) examined HR responses to a series of loud tones in Vietnam veterans with PTSD and their non-combat-exposed monozygotic twins. Only the twin with PTSD showed elevated HR response relative to combat-exposed veterans without PTSD and their non-exposed twins, suggesting that elevated HR response is an acquired sign of PTSD rather than a risk factor. However, further longitudinal studies where HR response is measured prior to trauma will be necessary to definitively rule out HR as a prospective marker of risk for PTSD. Pole et al. [\(2009](#page-24-0)) measured a number of physiological indices (startle, electrodermal response, HR) in response to startling tones under conditions of varying contextual threat (low, medium, and high threat of electrical shock) in new police academy cadets. These cadets were then later assessed for PTSD symptoms following one year of police work. They found that elevated startle measured by eyeblink EMG (with appropriate sampling rate), elevated electrodermal response, and slower habituation of the electrodermal response predicted PTSD symptom severity, but that HR response did not. Further, the associations between physiological reactivity and PTSD severity varied as a condition of the contextual threat: Greater electrodermal response was associated with PTSD symptom severity under low and high threat, and eyeblink EMG under medium threat was associated with symptom severity. These findings support the hypothesis that increased physiological reactivity to threat may be a useful marker for understanding biological mechanisms of PTSD risk.

Markers of Fear and Anxiety Constructs: Little is known about how abnormalities in safety learning and fear extinction may function as preexisting markers of risk for PTSD. A recent study found that impaired ability to inhibit fearpotentiated startle responding in the presence of a safety cue was associated with PTSD symptoms 2 and 9 months after combat-related trauma (Sijbrandij et al. [2013\)](#page-25-0). These findings suggest that impaired safety signal learning may be important in predicting the maintenance of PTSD symptoms over time. It is not clear, however, whether reductions in safety signal learning predict PTSD prospectively. Investigators have also begun to look at impaired fear extinction processes as risk factors for developing PTSD following trauma. A twin study of combat-related PTSD by Milad et al. [\(2008](#page-23-0)) suggested that reduced recall of fear extinction memory is an acquired sign of PTSD rather than a preexisting risk factor. Guthrie and Bryant ([2006\)](#page-22-0) examined initial fear extinction learning of an aversively conditioned corrugator EMG response in a sample of firefighter trainees. They found that slower extinction while in training predicted PTSD severity after later exposure to trauma. Lommen et al. [\(2013\)](#page-23-0) showed similar effects in a sample of Dutch combat veterans, though they only assessed explicit contingency awareness rather than physiological response. Further prospective–longitudinal studies assessing both habituation and extinction prior to trauma are needed to confirm whether or not these are robust markers of PTSD risk.

Summary of Risk Markers: While peri-traumatic physiological response may provide some information regarding who is at risk for developing chronic PTSD, more research is needed to solidify the extant findings and to link elevated physiology following trauma to specific biological changes underlying chronic disorder. Much less is known about using physiological markers to predict risk for PTSD prior to traumatic experience, though the results of Pole et al. [\(2009](#page-24-0)) provide promising avenues for future research in this area and suggest the possibility of achieving superior prediction by the integration of multiple psychophysiological domains into a single marker for risk. Knowing who is at risk for PTSD prior to trauma may have utility for screening of soldiers and first responders such as firefighters and police officers. Identification of pretrauma risk factors that are modifiable can inform prevention efforts in these and other populations at high risk for trauma exposure and may also point toward fruitful targets for novel treatment efforts.

5 Future Areas of Application for Psychophysiological Research

Psychophysiological Markers of Treatment Response: Beyond serving as markers of PTSD state or risk for developing the disorder, psychophysiological outcomes may have potential to provide objective markers of treatment response. This utility is particularly relevant as the NIMH now requires treatment studies to include biological and/or physiological markers along with standard symptom scales. To date, however, relatively few studies have made use of physiological outcome measures. To our knowledge, there are no reports of psychophysiological responses in PTSD patients during standard pharmacotherapies, e.g., serotonin reuptake inhibitors. Two recent studies using psychotherapy have included physiological markers. Robinson-Andrew et al. ([2014\)](#page-25-0) assessed potentiated startle responding in the presence of trauma-related visual cues in a small number of combat veterans with PTSD before, during, and after either prolonged exposure or "present-centered therapy" treatment. Treatment responders showed a dynamic pattern of increasing and then decreasing startle potentiation across treatment, while non-responders did not change. In another recent study, Rothbaum et al. [\(2014](#page-25-0)) compared the effects of d-cycloserine, alprazolam, and placebo on response to 5 sessions of prolonged exposure therapy for PTSD. Outcomes consisted of both self-reported diagnostic assessments as well as potentiated startle response to trauma-related images. The patients receiving d-cycloserine showed significantly lower startle potentiation post-treatment, and magnitude of startle reduction was associated with self-reported treatment response in this group only. However, groups did not differ on selfreported response to the treatment overall. There is no research yet on treatment effects on PTSD-related constructs of fear extinction or safety signal learning.

One earlier area of study where psychophysiological outcomes appeared promising was in predicting potential prophylactic efficacy of propranolol, a betaadrenergic receptor antagonist. Pitman et al. ([2002\)](#page-24-0) originally showed that propranolol given immediately after trauma reduced physiological arousal (HR, electrodermal response, facial EMG) to script-driven traumatic imagery 3 months later, as well as showing a nonsignificant trend toward reduced PTSD symptom severity 1 month following trauma. In a larger study, Hoge et al. [\(2012](#page-22-0)) showed mixed results when propranolol or placebo was given to emergency department patients for 19 days following trauma. In "high-medication adherence" subjects, those who took the active drug showed reduced physiological reactivity to trauma imagery across three domains (electrodermal response, HR, lateral frontalis EMG) at 1 month following trauma relative to those who received placebo. However, this difference was not found at 3 months post-trauma, nor was there an effect of treatment on PTSD symptoms. Given the very mixed literature for treatment efficacy of propranolol as a prophylactic treatment for PTSD (Vaiva et al. [2003;](#page-26-0) Stein et al. [2007;](#page-25-0) McGhee et al. [2009](#page-23-0)), the predictive validity of psychophysiological measures for propranolol prevention of PTSD symptoms is inconclusive. Current studies have now shifted to examination of propranolol effects on memory reconsolidation in PTSD patients ([www.clinicaltrials.gov\)](http://www.clinicaltrials.gov), based in part on recent findings that propranolol given immediately after reactivation of the trauma memory via script preparation reduces physiological responding to the same script one week later (Brunet et al. [2009](#page-20-0)).

Psychophysiological outcomes have also seen limited use in studies investigating potential novel treatments. Jovanovic et al. [\(2011](#page-22-0)) showed that dexamethasone treatment reduces fear-potentiated startle in PTSD patients, suggesting that this treatment could reduce physiological symptoms of fear in these patients. These results provide preliminary support for the predictive validity of fear-potentiated startle in PTSD, since glucocorticoid agonists may reduce PTSD symptoms (Aerni et al. [2004;](#page-19-0) Steckler and Risbrough [2012](#page-25-0)). An ongoing study is also assessing the efficacy of corticotropin-releasing factor receptor antagonist treatment on both PTSD symptoms and fear-potentiated startle (Dunlop et al. [2014\)](#page-21-0). We expect that more studies will utilize this complementary approach of physiological and self-report measures to assess treatment efficacy in the future.

Overall, psychophysiological outcomes have not been utilized in treatment studies and thus remain largely untested for sensitivity to treatment effects for PTSD. An important caveat is that some studies have shown a pattern of treatment-induced reductions in psychophysiological arousal, but not in self-reported PTSD symptom severity. This pattern of findings suggests several possibilities. First, psychophysiological alterations may not be powerful enough to generalize into symptom change per se (e.g., Hoge et al. [2012\)](#page-22-0). Second, psychophysiological alterations may be one of the several potential mechanisms of change occurring within the same treatment protocol (e.g., Rothbaum et al. [2014](#page-25-0)). These conclusions suggest that psychophysiological assessment may be used as an objective marker of treatment response and have utility in elucidating mechanism/process of change that may vary across subjects being treated with the same protocol. Further, psychophysiological

assessment may have utility for understanding which patients may benefit from among several treatment modalities aimed at the same overt condition (Aikens et al. 2011). More research is required before this approach can be considered a realistic possibility in the near term.

Consideration of Mild Traumatic Brain Injury (mTBI) in Psychophysiological Investigations of Trauma-related Pathology: Many of the traumatic experiences that might result in development of PTSD (motor vehicle accident, physical assault, combat) also involve potential for physical harm. The large numbers of blast-related injuries coming out of the wars in Iraq and Afghanistan (Hoge et al. [2008\)](#page-22-0) have brought into recent focus the potential relationship between mTBI and PTSD. A prospective study of service members deployed in these conflicts suggests a strong association between deployment-related mTBI and post-deployment PTSD symptoms (Yurgil et al. [2014](#page-26-0)). These findings suggest that mTBI may need to be considered as an important factor in assessing psychophysiological outcomes in PTSD, similar to its potential effects on neurocognitive symptoms in PTSD (Vasterling et al. [2009,](#page-26-0) [2012](#page-26-0)). Little research has been conducted on how mTBI affects the physiological markers discussed here, with the exception of HRV. HRV is reduced in some TBI patients, with alterations related to time since injury and injury severity (Keren et al. [2005;](#page-23-0) Baguley et al. [2006](#page-19-0)). One study in active duty marines with PTSD suggests that HRV is reduced in PTSD subjects even when controlling for TBI although TBI was also independently associated with reduced HRV (Minassian et al. [2014\)](#page-23-0). Williamson et al. [\(2013](#page-26-0)) have suggested that in cases of mTBI-induced damage to white matter tracts involved in emotional behavior (e.g., uncinate fasciculus and the anterior limb of the internal capsule) may cause disruption of topdown control of autonomic nervous system activity reflected in psychophysiological measurements. These forms of disruption could also explain the higher risk for development of PTSD in individuals exhibiting mTBI (Yurgil et al. [2014](#page-26-0)). Interestingly, recent animal studies have also supported that mild TBI could result in sensitization of fear learning processes (Heldt et al. [2014\)](#page-22-0). Thus, mTBI should be carefully considered in future assessments of PTSD-related physiology, particularly in abnormalities of cortical-mediated inhibitory processes and fear learning constructs, to understand its modulating or mediating role in psychophysiological abnormalities in PTSD.

Wearable Physiological Monitoring Technology: Although the specific physiological abnormalities linked to trauma symptoms are becoming more clear as reviewed above, one of the next steps for the field is to determine whether these measures can translate to clinical applications, such as prediction of symptom development, symptom class, and/or treatment response. Moving these measures to clinical applications faces significant hurdles, one of which is the development of more usable devices that are not dependent on narrow laboratory-specific parameters or expensive and complicated hardware. One potential area for psychophysiology variables in mental health in the future is use of "wearable" devices in subjects that have experienced, or at risk for, trauma (Darwish and Hassanien [2011\)](#page-20-0).

There is a strong push both in private and academic medical sectors to implement wearable devices for a host of medical purposes including diabetes, cardiovascular disease management, cognitive therapy aids, and other lifestyle aids for better wellness. Predictive psychophysiological variables relevant to PTSD phenotypes that may be conducive to wearable technology are measures of physical activity via accelerometers (e.g., Fukukawa et al. [2004](#page-21-0)), sleep (Suzuki et al. [2014\)](#page-26-0), skin conductance (Rajan et al. [2012\)](#page-25-0), HR and HRV (Billeci et al. [2014\)](#page-20-0), EMG (Grenier et al. [2012\)](#page-21-0), and EEG (Zao et al. [2014\)](#page-26-0). The development of these wearables will enable assessment of dynamics of physiology in naturalist settings, at rest (i.e., sleep) as well as during stress. These devices may help answer the question of which physiological variable, or combination of variables, might be able to predict development of PTSD symptoms after trauma exposure (e.g., after discharge from the ER/hospital). Another question is if physiological markers are sensitive to treatment, and when in the recovery process does this happen (i.e., could these markers serve as early predictors of treatment response?). Many of these variables are not "static," for example, longer-term assessment of sleep variance across multiple nights will enable a much more comprehensive picture than can feasibly be obtained in laboratory settings. Similarly, HRV over long time periods will provide greater fidelity in the assessment of cardiovascular changes after trauma. Some wearable devices may also be utilized in "at-risk" populations, such as rescue service and military personnel, to develop algorithms of risk based on physiological response and recovery after trauma exposure. This approach is currently being examined in the military (Tharion et al. [2013\)](#page-26-0). However, a number of hurdles must be considered in terms of feasibility/practicality of the technology, the data quality, storage capacity, and of course the ethical component of resulting data being used or stored improperly.

One example of current status of technology is assessment of continuous HR. HRV can now be obtained via sophisticated wearable devices (e.g., pulse oximeter introduced into a wrist watch) over long periods of time with little burden to the subject. However, technical challenges must be addressed, including the high sampling rate needed for HRV assessments that can produce power and data storage limitations for continuous monitoring. Data quality is also affected significantly by movement artifact for many of these devices. Thus, despite significant promise, many technical limitations must be addressed before these devices will produce reliable physiological assessments for utility in prediction and intervention.

6 Conclusion

As discussed above, there are now a number of well-validated physiological phenotypes that are reliable across multiple studies/laboratories, including increased and poorly inhibited physiological responses to threat (electrodermal and EMG), as well as altered HRV. We are just now beginning to understand these measures in a larger context of symptom domains, as well as comorbid symptoms (depression, TBI, etc.).

Much more work is needed, however, to refine these phenotypes in terms of specific associations with PTSD symptoms versus other anxiety disorders and comorbid symptoms (depression, TBI). Importantly, many of these phenotypes are now well mapped to circuitry that supports translational research across species for mechanisms driving these phenotypes, which will support development of novel treatment targets. To this end, psychophysiological measures are increasingly being used as complementary measures for integration with both self-report and other biological assessments (e.g., blood-based or genetic markers). We expect much more research in the years to come with these tools for objective assessment of treatment outcome. Finally, in the long term, wearable technology could accelerate the feasibility of these markers as tools to identify risk and symptom development in clinical settings.

Acknowledgments This work was supported by MH074697, MH042228, VA BLR&D Merit Award, and a NARSAD Young Investigator Award.

References

- Acheson DT, Gresack JE, Risbrough VB (2012) Hippocampal dysfunction effects on context memory: possible etiology for posttraumatic stress disorder. Neuropharmacology 62:674–685
- Acheson DT, Feifel D, de Wilde S, McKinney R, Lohr J, Risbrough VB (2013) The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology 229:199–208
- Adenauer H, Catani C, Keil J, Aichinger H, Neuner F (2010) Is freezing an adaptive reaction to threat? Evidence from heart rate reactivity to emotional pictures in victims of war and torture. Psychophysiology 47:315–322
- Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A, Nitsch RM, Schnyder U, de Quervain DJF (2004) Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 161:1488–1490
- Agorastos A, Boel JA, Heppner PS, Hager T, Moeller-Bertram T, Haji U, Motazedi A, Yanagi MA, Baker DG, Stiedl O (2013) Diminished vagal activity and blunted diurnal variation of heart rate dynamics in posttraumatic stress disorder. Stress 16:300–310
- Ahmari SE, Risbrough VB, Geyer MA, Simpson HB (2012) Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder. Neuropsychopharmacology 37:1216–1223
- Argyle N (1991) Skin conductance levels in panic disorder and depression. J Nerv Ment Dis 179:563–566
- Andero R, Brothers SP, Jovanovic T, Chen YT, Salah-Uddin H, Cameron M, Bannister TD, Almli L, Stevens JS, Bradley B, Binder EB, Wahlestedt C, Ressler KJ (2013) Amygdala-Dependent fear Is regulated by oprl1 in mice and humans with PTSD. Sci Transl Med 5:188ra73
- Baguley IJ, Heriseanu RE, Felmingham KL, Cameron ID (2006) Dysautonomia and heart rate variability following severe traumatic brain injury. Brain Inj 20:437–444
- Baker DG, Heppner P, Afari N, Nunnink S, Kilmer M, Simmons A, et al. (2009) Trauma exposure, branch of service, and physical injury in relation to mental health among US veterans returning from Iraq and Afghanistan. Mil Med 174:773−778
- Baker DG, Nievergelt CM, O'Connor DT (2012) Biomarkers of PTSD: neuropeptides and immune signaling. Neuropharmacology 62:663–673
- Barkay G, Freedman N, Lester H, Louzoun Y, Sapoznikov D, Luckenbaugh D, Shalev AY, Chisin RG, Bonne O (2012) Brain activation and heart rate during script-driven traumatic imagery in PTSD: preliminary findings. Psychiatry Res Neuroimaging 204:155–160
- Berntson GG, Bigger JT, Eckberg DL, Grossman P, Kaufmann PG, Malik M, Nagaraja HN, Porges SW, Saul JP, Stone PH, van der Molen MW (1997) Heart rate variability: origins, methods, and interpretive caveats. Psychophysiology 34:623–648
- Billeci L, Tartarisco G, Brunori E, Crifaci G, Scardigli S, Balocchi R, Pioggia G, Maestro S, Morales MA (2014) The role of wearable sensors and wireless technologies for the assessment of heart rate variability in anorexia nervosa. Eat Weight Disord (Epub ahead of print)
- Blakeley K, Jansen DJ (2013) Post-traumatic stress disorder and other mental health problems in the military: oversight issues for congress. Congressional research service report
- Blanchard EB, Kolb LC, Pallmeyer TP, Gerardi RJ (1982) A psychophysiological study of posttraumatic stress disorder in Vietnam veterans. Psychiatr Q 54:220–229
- Blanchard EB, Hickling EJ, Galovski T, Veazey C (2002) Emergency room vital signs and PTSD in a treatment seeking sample of motor vehicle accident survivors. J Trauma Stress 15:199–204
- Blechert J, Michael T, Vriends N, Margraf J, Wilhelm FH (2007) Fear conditioning in posttraumatic stress disorder: Evidence for delayed extinction of autonomic, experiential, and behavioural responses. Behav Res Ther 45:2019–2033
- Blumenthal TD, Cuthbert BN, Filion DL, Hackley S, Lipp OV, van Boxtel A (2005) Committee report: guidelines for human startle eyeblink electromyographic studies. Psychophysiology 42:1–15
- Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156:234–258
- Breslau N (2009) The epidemiology of trauma, PTSD, and other posttrauma disorders. Trauma Violence Abuse 10:198–210
- Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK (2009) Effect of post-retrieval propranolol on pscyhophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 42:503–506
- Bryant RA, Harvey AG, Guthrie RM, Moulds ML (2000) A prospective study of psychophysiological arousal, acute stress disorder, and posttraumatic stress disorder. J Abnorm Psychol 109:342–344
- Buckley TC, Kaloupek DG (2001) A meta-analytic examination of basal cardiovascular activity in posttraumatic stress disorder. Psychosom Med 63:585–594
- Buckley TC, Holohan D, Grei, JL, Bedard M, Suvak M (2004) Twenty-four hour ambulatory assessment of heart rate and blood pressure in chronic PTSD and non-PTSD veterans. J Trauma Stress 17:163–171
- Butler RW, Braff DL, Rausch JL, Jenkins MA, Sprock J, Geyer MA (1990) Physiological evidence of exaggerated startle response in a subgroup of Vietnam veterans with combatrelated PTSD. Am J Psychiatry 147:1308–1312
- Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M (1996) Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 39:33–41
- Chang HA, Chang CC, Tzeng NS, Kuo TB, Lu RB, Huang SY (2013) Decreased cardiac vagal control in drug-naive patients with posttraumatic stress disorder. Psychiatry Investig 10:121–130
- Cohen H, Benjamin J, Geva AB, Matar MA, Kaplan Z, Kotler M (2000) Autonomic dysregulation in panic disorder and in post-traumatic stress disorder: application of power spectrum analysis of heart rate variability at rest and in response to recollection of trauma or panic attacks. Psychiatry Res 96:1–13
- Cuthbert BN, Lang PJ, Strauss C, Drobes D, Patrick CJ, Bradley MM (2003) The psychophysiology of anxiety disorder: fear memory imagery. Psychophysiology 40:407–422
- Darwish A, Hassanien AE (2011) Wearable and implantable wireless sensor network solutions for healthcare monitoring. Sensors 11:5561–5595
- Davis M, Walker DL, Miles L, Grillon C (2010) Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology 35:105–135
- de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH (2011) Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 108:6621–6625
- Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS (2014) Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials 15:240
- Ehlers A, Suendermann O, Boellinghaus I, Vossbeck-Elsebusch A, Gamer M, Briddon E, Martin M, Glucksman E (2010) Heart rate responses to standardized trauma-related pictures in acute posttraumatic stress disorder. Int J Psychophysiol 78:27–34
- Ehring T, Ehlers A, Cleare AJ, Glucksman E (2008) Do acute psychological and psychobiological responses to trauma predict subsequent symptom severities of PTSD and depression? Psychiatry Res 161:67–75
- Eraly SA, Nievergelt CM, Maihofer AX, Barkauskas DA, Biswas N, Agorastos A, O'Connor DT, Baker DG (2014) Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry 71:423–431
- Fukukawa Y, Nakashima C, Tsuboi S, Kozakai R, Doyo W, Niino N, Ando F, Shimokata H (2004) Age differences in the effect of physical activity on depressive symptoms. Psychol Aging 19:346–351
- Geracioti Jr TD, Baker DG, Kasckow JW, Strawn JR, Mulchahey J, Dashevsky BA, Horn PS, Ekhator NN (2008) Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder. Psychoneuroendocrinology 33:416–424
- Geracioti TD, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck PE, Kasckow JW (2001) CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 158:1227–1230
- Geyer MA, Braff DL (1982) Habituation of the Blink reflex in normals and schizophrenic patients. Psychophysiology 19:1–6
- Geyer MA, Braff DL (1987) Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophr Bull 13:643–668
- Geyer MA, Swerdlow NR, Mansbach RS, Braff DL (1990) Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res Bull 25:485–498
- Glover EM, Phifer JE, Crain DF, Norrholm SD, Davis M, Bradley B, Ressler KJ, Jovanovic T (2011) Tools for translational neuroscience: PTSD is associated with heightened fear responses using acoustic startle but not skin conductance measures. Depress Anxiety 28:1058–1066
- Gould NF, McKibben JB, Hall R, Corry NH, Amoyal NA, Mason ST, McCann UD, Fauerbach JA (2011) Peritraumatic heart rate and posttraumatic stress disorder in patients with severe burns. Clin Psychiatry 72:539–547
- Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME et al (2007) Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry 64:1242–1250
- Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff DL (2012) Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS ONE 7:e29630
- Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME et al (2013) Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 170:521–532
- Grenier JG, Millet GY, Peyrot N, Samozino P et al (2012) Effects of extreme-duration heavy load carriage on neuromuscular function and locomotion: a military-based study. PLoS ONE 7: e43586
- Grillon C, Morgan CA, Southwick SM, Davis M, Charney DS (1996) Baseline startle amplitude and prepulse inhibition in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res 64:169–178
- Grillon C, Morgan CA, Davis M, Southwick SM (1998) Effects of experimental context and explicit threat cues on acoustic startle in Vietnam veterans with posttraumatic stress disorder. Biol Psychiatry 44:1027–1036
- Grillon C, Baas J (2003) A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol 114:1557–1579
- Grillon C (2008) Greater sustained anxiety but not phasic fear in women compared to men. Emotion 8:410–413
- Grillon C, Pine DS, Lissek S, Rabin S, Bonne O, Vythillingham M (2009) Increased anxiety during anticipation of unpredictable aversive stimuli in posttraumatic stress disorder but not in generalized anxiety disorder. Biol Psychiatry 66:47–53
- Guthrie RM, Bryant RA (2006) Extinction learning before trauma and subsequent posttraumatic stress disorder. Psychosom Med 68:307–311
- Haaker J, Gaburro S, Sah A, Gartman N, Lonsdorf TB, Meier K, Singewald N, Pape HC, Morellini F, Kalisch R (2013) Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear. Proc Natl Acad Sci 110:E2423–E2436
- Halberstadt AL, Geyer MA (2009) Habituation and sensitization of acoustic startle: opposite influences of dopamine D1 and D2-family receptors. Neurobiol Learn Mem 92:243–248
- Heathers JA (2014) Everything Hertz: methodological issues in short-term frequency-domain HRV. Front Physiol 5:177
- Heldt SA, Elberger AJ, Deng Y, Guley NH, Del Mar N, Rogers J, Choi GW, Ferrell J, Rex TS, Honig MG, Reiner A (2014) A novel closed-head model of mild traumatic brain injury caused by primary overpressure blast to the cranium produces sustained emotional deficits in mice. Front Neurol 5:2
- Hoge EA, McGurk D, Thomas JL, Cox AL, Engel CC, Castro CA (2008) Mild traumatic brain injury in US soldiers returning from Iraq. N Engl J Med 358:453–463
- Hoge EA, Worthington JJ, Nagurney JT, Chang Y, Kay EB, Feterowski CM, Katzman AR, Goetz JM, Rosasco ML, Lasko NB, Zusman RM, Pollack MH, Orr SP, Pitman RK (2012) Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during scriptdriven imagery. CNS Neurosci Ther 18:21–27
- Holstein DH, Vollenweider FX, Jancke L, Schopper C, Csomor PA (2010) P50 suppression, prepulse inhibition, and startle reactivity in the same patient cohort suffering from posttraumatic stress disorder. J Affect Disord 126:188–197
- Holt DJ, Lebron-Milad K, Milad MR, Rauch SL, Pitman RK, Orr SP, Cassidy BS, Walsh JP, Goff DC (2009) Extinction memory is impaired in schizophrenia. Biol Psychiatry 65:455–463
- Jovanovic T, Norrholm SD, Sakoman AJ, Esterajher S, Kozaric-Kovacic D (2009) Altered resting psychophysiology and startle response in Croatian combat veterans with PTSD. Int J Psychophysiol 71:264–268
- Jovanovic T, Norrholm SD, Blanding NQ, Davis M, Duncan E, Bradley B, Ressler KJ (2010) Impaired fear inhibition is a biomarker of PTSD but not depression. Depress Anxiety 27:244–251
- Jovanovic T, Phifer JE, Sicking K, Weiss T, Norrholm SD, Bradley B, Ressler KJ (2011) Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology 36:1540–1552
- Jovanovic T, Ely T, Fani N, Glover EM, Gutman D, Tone EB, Norrholm SD, Bradley B, Ressler KJ (2013) Reduced neural activation during an inhibition task is associated with impaired fear inhibition in a traumatized civilian sample. Cortex 49:1884–1891
- Kamkwalala A, Norrholm SD, Poole JM, Brown A, Donley S, Duncan E, Bradley B, Ressler KJ, Jovanovic T (2012) Dark-enhanced startle responses and heart rate variability in a traumatized civilian sample: putative sex-specific correlates of posttraumatic stress disorder. Psychosom Med 74:153–159
- Kamphuis MH, Geerlings MI, Tijhuis MA, Giampaoli S, Nissinen A, Grobbee DE, Kromhout D (2007) Physical inactivity, depression, and risk of cardiovascular mortality. Med Sci Sports Exerc 39:1693–1699
- Kassam-Adams N, Garcia-Espana JF, Fein JA, Winston FK (2005) Heart rate and posttraumatic stress in injured children. Arch Gen Psychiatry 62:335–340
- Keren O, Yupatov S, Radai MM, Elad-Yarum R, Faraggi D, Abboud S, Ring H, Groswasser Z (2005) Heart rate variability (HRV) of patients with traumatic brain injury (TBI) during the post-insult sub-acute period. Brain Inj 19:605–611
- Khoury NM, Marvar PJ, Gillespie CF, Wingo A, Schwartz A, Bradley B, Kramer M, Ressler KJ (2012) The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J Clin Psychiatry 73:849–855
- Klumpers F, Raemaekers MA, Ruigrok AN, Hermans EJ, Kenemans JL, Baas JM (2007) Prefrontal mechanisms of fear reduction after threat onset. Biol Psychiatry 68:1031–1038
- Kohl S, Heekeren K, Klosterkötter J, Kuhn J (2013) Prepulse inhibition in psychiatric disorders-Apart from schizophrenia. J Psychiatr Res 47:445–452
- Kubzansky LD, Koenen KC, Spiro A, Vokonas PS, Sparrow D (2007) Prospective study of posttraumatic stress disorder symptoms and coronary heart disease in the Normative Aging Study. Arch Gen Psychiatry 64:109–116
- Kuhn E, Blanchard EB, Fuse T, Hickling EJ, Broderick J (2006) Heart rate of motor vehicle accident survivors in the emergency department, peritraumatic psychological reactions, ASD, and PTSD severity: a 6-month prospective study. J Trauma Stress 19:735–740
- Liberzon I, Taylor SF, Amdur RL, Jung TD, Chamberlain KR, Minoshima S et al (1999) Brain activation in PTSD in response to trauma-related stimuli. Biol Psychiatry 45:817–826
- Lipschitz DS, Mayes LM, Rasmusson AM, Anyan W, Billingslea E, Gueorguieva R, Southwick SM (2005) Baseline and modulated acoustic startle responses in adolescent girls with posttraumatic stress disorder. J Am Acad Child Adol Psychiatry 44:807–814
- Lommen MJ, Engelhard IM, Sijbrandij M, van den Hout MA, Hermans D (2013) Pre-trauma individual differences in extinction learning predict posttraumatic stress. Behav Res Ther 51:63–67
- Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX (2002) Prepulse inhibition deficits in patients with panic disorder. Depress Anxiety 15:55–60
- Ludewig K, Geyer MA, Etzensberger M, Vollenweider FX (2002). Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res 55:129–137
- Ludewig K, Geyer MA, Vollenwweider FX (2003) Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry 54:121−128
- Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Cattapan-Ludewig K (2005) Information-processing deficits and cognitive dysfunction in panic disorder. J Psychiatry Neurosci 30:37–43
- McEwen BS (2000) Allostasis and allostatic load: implications for neuropsychopharmacology. Neuropsychopharmacology 22:108–124
- McGhee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH (2009) The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res 30:92–97
- McTeague LM, Lang PJ, Laplante MC, Cuthbert BN, Shumen JR, Bradley MM (2010) Aversive imagery in posttraumatic stress disorder: Trauma recurrence, comorbidity, and physiological reactivity. Biol Psychiatry 15:346–356
- Milad MR, Orr SP, Lasko NB, Chang Y, Rauch SL, Pitman RK (2008) Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res 42:515–520
- Milad MR, Furtak SC, Greenberg JL, Keshaviah A, Im JJ, Falkstein MJ, Jenike M, Rauch SL, Wilhelm S (2013) Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurological changes in the fear circuit. JAMA Psychiatry 70:608–618
- Minassian A, Geyer MA, Baker DG, Nievergelt CM, O'Connor DT, Risbrough VB, MRS Team (2014) Heart rate variability characteristics in a large group of active-duty Marines and relationship to posttraumatic stress. Psychosom Med 76:292–301
- Moon E, Lee SH, Kim DH, Hwang B (2013) Comparative study of heart rate variability in patients with schizophrenia, bipolar disorder, post-traumatic stress disorder, or major depressive disorder. Clin Psychopharmacol Neurosci 11:137–143
- Morgan CA, Grillon C, Southwick SM, Nagy LM, Davis M, Krystal JH, Charney DS (1995) Yohimbine facilitated acoustic startle in combat veterans with post-traumatic stress disorder. Psychopharmacology 117:466–471
- Morgan CA, Grillon C, Lubin H, Southwick SM (1997) Startle reflex abnormalities in women with sexual assault-related posttraumatic stress disorder. Am J Psychiatry 154:1076–1080
- Muraoka MY, Carlson JG, Chemtob CM (1998) Twenty-four hour ambulatory blood pressure and heart rate monitoring in combat-related posttraumatic stress disorder. J Trauma Stress 11:473–484
- Norrholm SD, Jovanovic T, Olin IW, Sands LA, Karapanou I, Bradley B, Ressler KJ (2011) Fear extinction in traumatized civilians with posttraumatic stress disorder: relation to symptom severity. Biol Psychiatry 69:556–563
- Ornitz EM, Pynoos R (1989) Startle modulation in children with Post-traumatic Stress Disorder. Am J Psychiatry 146:866–870
- Orr SP, Pitman RK (1993) Psychophysiologic assessment of attempts to simulate posttraumatic stress disorder. Biol Psychiatry 33:127–129
- Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T, Pitman RK (2000) De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 109:290–298
- Orr SP, Metzger LJ, Pitman RK (2002) Psychophysiology of post-traumatic stress disorder. Psychiatr Clin N Am 25:271–293
- Pallmeyer TP, Blanchard EB, Kolb LC (1986) The psychophysiology of combat-induced posttraumatic stress disorder in Vietnam veterans. Behav Res Therapy 24:645–652
- Peri T, Ben-Shakhar G, Orr SP, Shalev AY (2000) Psychophysiologic assessment of aversive conditioning in posttraumatic stress disorder. Biol Psychiatry 47:512–519
- Perry W, Minassian A, Feifel D, Braff DL (2001) Sensorimotor gating deficits in bipolar disorder patients with acute psychotic mania. Biol Psychiatry 50:418–424
- Pietrzak RH, Gallezot JD, Ding YS, Henry S, Potenza MN, Southwick SM, Krystal JH, Carson RE, Neumeister A (2013) Association of posttraumatic stress disorder with reduced in vivo norepinephrine availability in the locus coeruleus. JAMA Psychiatry 70:1199–1205
- Pitman RK, Orr SP, Forgue DF, Altman B, de Jong JB, Claiborn JM (1987) Psychophysiologic assessment of posttraumatic stress disorder imagery in Vietnam combat veterans. Arch Gen Psychiatry 44:970–975
- Pitman RK, Orr SP, Lasko NB (1993) Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with posttraumatic stress disorder. Psychiatry Res 48:107
- Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB et al (2002) Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51:189–192
- Pitman RK, Gilbertson MW, Gurvits TV, May FS, Lasko NB, Metzger LJ, Shenton ME, Yehuda R, Orr SP (2006) Clarifying the origin of biological abnormalities in PTSD through the study of identical twins discordant for combat exposure. Ann NY Acad Sci 1071:242–254
- Pittig A, Arch JJ, Lam CWR, Craske MG (2013) Heart rate and heart rate variability in panic, social anxiety, obsessive-compulsive, and generalized anxiety disorders at baseline and in response to relaxation and hyperventilation. Int J Psychophysiol 87:19–27
- Pole N (2007) The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychol Bull 133:725–746
- Pole N, Neylan TC, Otte C, Henn-Hasse C, Metzler TJ, Marmar CR (2009) Prospective prediction of posttraumatic stress disorder symptoms using fear potentiated auditory startle responses. Biol Psychiatry 65:235–240
- Price M, Kearns M, Houry D, Rothbaum BO (2014) Emergency department predictors of posttraumatic stress reduction for trauma-exposed individuals with and without an early intervention. J Consult Clin Psychol 82:336–341
- Quirk GJ, Garcia R, Gonzalez-Lima F (2006) Prefrontal mechanisms in extinction of conditioned fear. Biol Psychiary 60:337–343
- Rabinak CA, Angstadt M, Sripada CS, Abelson JL, Liberzon I, Milad MR, Phan KL (2013) Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 64:396–402
- Rajan S, Leonard N, Fletcher R, Casarjian B, Casarjian R, Cisse C, Gwadz M (2012) Ambulatory autonomic activity monitoring among at-risk adolescent mothers. J Mob Technol Med 1:25–31
- Raskind MA, Peterson K, Williams T, Hoff DJ, Hart K, Holmes H, Homas D, Hill J, Daniels C, Calohan J, Millard SP, Rohde K, O'Connell J, Pritzi D, Feiszil K, Petrie EC, Gross C, Mayer CL, Freed MC, Engel C, Peskind ER (2013) A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry 170:1003–1010
- Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, Ramirez M, Engel A, Hammack SE, Toufexis D, Braas KM, Binder EB, May V (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470:492–497
- Risbrough VB, Stein MB (2006) Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav 50:550–561
- Robison-Andrew EJ, Duval ER, Nelson CB, Echiverri-Cohen A, Giardino N, Defever A, Norrholm SD, Jovanovic T, Rothbaum BO, Liberzon I, Rauch SAM (2014) Changes in trauma-potentiated startle with treatment of posttraumatic stress disorder in combat veterans. J Anxiety Disord 28:358–362
- Roitman P, Gilad M, Ankri YL, Shalev AY (2013) Head injury and loss of consciousness raise the likelihood of developing and maintaining PTSD symptoms. J Trauma Stress 26:727–734
- Rothbaum BO, Price M, Jovanovic T, Norrholm SD, Gerardi M, Dunlop B, Davis M, Bradley B, Duncan EJ, Rizzo A, Ressler KJ (2014) A randomized, double-blind evaluation of Dcycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan war veterans. Am J Psychiatry 171:640–648
- Sahar ME, Shalev AY, Porges SW (2001) Vagal modulation of responses to mental challenge in posttraumatic stress disorder. Biol Psychiatry 49:637–643
- Shah AJ, Lampert R, Goldberg J, Veledar E, Bremner JD, Vaccarino V (2013) Posttraumatic stress disorder and impaired autonomic modulation in male twins. Biol Psychiatry 73:1103–1110
- Shalev AY, Orr SP, Peri T, Schreiber S, Pitman RK (1992) Physiologic responses to loud tones in Israeli patients with posttraumatic stress disorder. Arch Gen Psychiatry 49:870–875
- Shalev AY, Sahar T, Freedman S, Peri T, Glick N, Brandes D, Orr SP, Pitman RK (1998) A prospective study of heart rate response following trauma and the subsequent development of posttraumatic stress disorder. Arch Gen Psychiatry 55:5533–5559
- Shalev AY, Peri T, Brandes D, Freedman S, Orr SP, Pitman RK (2000) Auditory startle response in trauma survivors with posttraumatic stress disorder: a prospective study. Am J Psychiatry 157:255–261
- Shin LM, Rauch SL, Pitman RK (2006) Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann NY Acad Sci 1071:67–79
- Sijbrandij M, Engelhard IM, Lommen MJ, Leer A, Baas JM (2013) Impaired fear inhibition learning predicts the persistence of symptoms of posttraumaticstress disorder (PTSD). J Psychiatr Res 47:1991–1997
- Solovieff N, Roberts AL, Ratanatharathorn A, Haloosim M, De Vivo I et al (2014) Genetic Association Analysis of 300 genes identifies a risk haplotype in SLC18A2 for post-traumatic stress disorder in two independent samples. Neuropsychopharmacology 39:1872–1879
- Steckler T, Risbrough VB (2012) Pharmacological treatment of PTSD—established and new approaches. Neuropharmacology 62:617−627
- Stein MB, Kerridge C, Dimsdale JE, Hoyt DB (2007) Pharmacotherapy to prevent PTSD: results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 20:923–932
- Suendermann O, Ehlers A, Boelinghaus I, Gamer M, Glucksman E (2010) Early heart rate response to standardized trauma-related pictures predict posttraumatic stress disorder—A prospective study. Psychosom Med 72:301–308
- Suzuki G, Tokuno S, Nibuya M, Ishida T, Yamamoto T, Mukai Y, Mitani K, Tsumatori G, Scott D, Shimizu K (2014) Decreased plasma brain-derived neurotrophic factor and vascular endothelial growth factor concentrations during military training. PLoS ONE 9:e89455
- Swerdlow NR, Talledo J, Sutherland AN, Nagy D, Shoemaker JM (2006) Anti-psychotic effects on prepulse inhibition in normal 'low gating' humans and rats. Neuropsychopharmacology 31:2011–2021
- Tharion WJ, Potter AW, Duhamel CM, Karis AJ, Buller MJ, Hoyt RW (2013) Real-time physiological monitoring while encapsulated in personal protective equipment. J Sport Human Perform
- Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar CR (2003) Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 54:947–949
- Vasterling JJ, Verfaellie M, Sullivan KD (2009) Mild traumatic brain injury and posttraumatic stress disorder in returning veterans: perspectives from cognitive neuroscience. Clin Psychol Rev 29:674–684
- Vasterling JJ, Brailey K, Proctor SP, Kane R, Heeren T, Franz M (2012) Neuropsychological outcomes of mild traumatic brain injury, post-traumatic stress disorder and depression in Iraqdeployed US Army soldiers. Br J Psychiatry 201:186–192
- Vrana SR, Calhoun PS, McClernon FJ, Dennis MF, Lee ST, Beckham JC (2013) Effects of smoking on the acoustic startle response and prepulse inhibition in smokers with and without posttraumatic stress disorder. Psychopharmacology 230:477–485
- Wentworth BA, Stein MB, Redwine LS, Xue Y, Taub PR, Clopton P, Nayak KR, Maisel AS (2013) Post-traumatic stress disorder: a fast track to premature cardiovascular disease? Cardiol Rev 21:16–22
- Wessa M, Flor H (2007) Failure of extinction of fear responses in posttraumatic stress disorder: evidence from second-order conditioning. Am J Psychiatry 164:1684–1692
- Williamson JB, Heilman KM, Porges EC, Lamb DG, Porges SW (2013) A possible mechanism for PTSD symptoms in patients with traumatic brain injury: central autonomic network disruption. Front Neuroengineering 6:1–9
- Yurgil KA, Barkauskas DA, Vasterling JJ, Nievergelt CM, Larson GE, Schork NJ, Litz BT, Nash WP, Baker DG, MRS Team (2014) Association between traumatic brain injury and risk of posttraumatic stress disorder in active-duty Marines. JAMA Psychiatry 71:149–157
- Zao JK, Gan TT, You CK, Chung CE, Wang YT, Rodríguez Méndez SJ, Mullen T, Yu C, Kothe C, Hsiao CT, Chu SL, Shieh CK, Jung TP (2014) Pervasive brain monitoring and data sharing based on multi-tier distributed computing and linked data technology. Front Hum Neurosci 8:370
- Zatzick DF, Russo J, Pitman RK, Rivara F, Jurovich G, Roy-Byrne P (2005) Reevaluating the association between emergency department heart rate and the development of posttraumatic stress disorder: a public health approach. Biol Psychiatry 57:91–95
- Zoladz PR, Diamond DM (2013) Current status on behavioral and biological markers of PTSD: a search for clarity in a conflicting literature. Neurosci Biobehav Revi 37:860–895